ESTHER
CHAMORRO DE VEGA
Profesora asociada de Ciencias de la Salud
Carmen Guadalupe
Rodríguez González
Publicaciones en las que colabora con Carmen Guadalupe Rodríguez González (14)
2023
-
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
Pharmacological Reports, Vol. 75, Núm. 5, pp. 1254-1264
2022
-
Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid
Annals of Pharmacotherapy, Vol. 56, Núm. 4, pp. 401-411
-
Implementation and evaluation of a home pharmaceutical care model through Telepharmacy
Farmacia Hospitalaria, Vol. 46, pp. 36-46
2021
-
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid
International Journal of Antimicrobial Agents, Vol. 57, Núm. 2
-
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260
2020
-
A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis
Medical Mycology, Vol. 58, Núm. 3, pp. 300-309
-
Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients
Annals of Pharmacotherapy, Vol. 54, Núm. 7, pp. 633-643
-
Hepatitis C virus infection and the role of a pharmaceutical care program
American Journal of Health-System Pharmacy, Vol. 77, Núm. 6, pp. 479-486
-
Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury
American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671
2018
-
Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients
Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18
-
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study
Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241
2017
-
Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project
International Journal of Clinical Practice, Vol. 71, Núm. 8
-
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks
International Journal of Clinical Practice, Vol. 71, Núm. 8
2016
-
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice
Annals of Pharmacotherapy, Vol. 50, Núm. 11, pp. 901-908